TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10211515

Group type: EXPERIMENTAL
Intervention: Medical bowel confinement (clear liquid diet with loperamide 4 mg three times per day and codeine phosphate 30 mg four times per day until the third postoperative day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Regular diet (beginning the day of surgery)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Medical bowel confinement
Number of subjects: 54

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 54
Study: 7789055

Group type: EXPERIMENTAL
Intervention: Natural estradiol (0.05 mg/day) for 6 months
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Natural estradiol (0.05 mg/day) and medroxyprogesteron acetate (10 mg/day) for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 40
Study: 2290770

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dummy intervention (control group)
Number of subjects: 0
Study: 113806

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia with naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypnotic analgesia with placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stress with naloxone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stress with placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anxiety measures
Number of subjects: 10
Study: 6357258

Group type: EXPERIMENTAL
Intervention: Combination of penbutolol and frusemide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Penbutolol alone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Frusemide alone
Number of subjects: 41
Study: 31340789

Group type: EXPERIMENTAL
Intervention: Probiotic strains Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, administered orally (one capsule daily) until negative HR-HPV testing.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo preparation, administered orally (one capsule daily) until negative HR-HPV testing.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Probiotic strains Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 121
Study: 30003583

Group type: EXPERIMENTAL
Intervention: Surgical debridement with bone substitute (Endobon®)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Surgical debridement (control group)
Number of subjects: 41
Study: 26779915

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with vaginal spheres (spheres group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pelvic floor muscle training without vaginal spheres (control group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (both groups)
Number of subjects: 70
Study: 24949949

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22974092

Group type: EXPERIMENTAL
Intervention: irinotecan with the Nordic bolus 5‐fluorouracil (5‐FU) and folinic acid schedule (FLIRI)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: de Gramont schedule (Lv5FU2‐IRI)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Changes in tumor marker levels during treatment
Number of subjects: 106
Study: 21990564

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) with up to 0.9 mg/kg alteplase over 60 min
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT) with alteplase according to European labeling
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 54
Study: 18585499

Group type: EXPERIMENTAL
Intervention: NT‐proBNP testing (n = 241)
Number of subjects: 477
Study: 15589080

Group type: EXPERIMENTAL
Intervention: Simultaneous Care (SC) cohort
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual Care (UC) cohort
Number of subjects: 44
Study: 11134261

Group type: EXPERIMENTAL
Intervention: Profiled dialysate sodium and ultrafiltration
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Profiled treatments
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 33
Study: 8995117

Group type: EXPERIMENTAL
Intervention: Endoscopic surveillance after ileorectal anastomosis or ileoanal pouch anastomosis
Number of subjects: 0
Study: 8485825

Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment (specific drug not mentioned)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ACE inhibitor treatment (enalapril)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg) in patients with essential hypertension
Number of subjects: 48
Study: 2892518

Group type: EXPERIMENTAL
Intervention: Alcuronium 2 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Pancuronium 1 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Vecuronium 1 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Suxamethonium-associated side effects prevention
Number of subjects: 160
Study: 27824485

Group type: EXPERIMENTAL
Intervention: Secretin-enhanced MRCP
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched subjects without recurrent acute pancreatitis or chronic pancreatitis)
Number of subjects: 72
Study: 27096729

Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fractional CO2 laser
Number of subjects: 25
Study: 25062783

Group type: EXPERIMENTAL
Intervention: Inhaler reminders and feedback (IRF)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Personalized adherence discussions (PADs)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Active usual care alone (Control)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Overall asthma control (all groups)
Number of subjects: 143
Study: 22275291

Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg or 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20530391

Group type: EXPERIMENTAL
Intervention: Facilitated implementation approach
Number of subjects: 36

Group type: COMPARATOR
Intervention: Self-directed implementation approach
Number of subjects: 36
Study: 17975960

Group type: EXPERIMENTAL
Intervention: Uvulopalatoplasty with CO2 laser
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 21
Study: 15802479

Group type: EXPERIMENTAL
Intervention: Evidence-based electronic reminders for diabetes care
Number of subjects: 6748

Group type: EXPERIMENTAL
Intervention: Evidence-based electronic reminders for CAD care
Number of subjects: 6748

Group type: EXPERIMENTAL
Intervention: Overall diabetes care compliance
Number of subjects: 6748

Group type: EXPERIMENTAL
Intervention: Overall CAD care compliance
Number of subjects: 6748

Group type: EXPERIMENTAL
Intervention: Physician attitudes toward the reminder system
Number of subjects: 6748

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 6748
Study: 12362115

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (100 units)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 9
Study: 9881427

Group type: EXPERIMENTAL
Intervention: New system B
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: New system C
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional system A
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All systems (A, B, C)
Number of subjects: 34
Study: 8306547

Group type: EXPERIMENTAL
Intervention: Microdialysis ethanol technique
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 133Xe clearance
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ethanol outflow/inflow ratio
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dialysate glucose concentration
Number of subjects: 6
Study: 2899390

Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31394602

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 1.5 atmospheres absolute, >99% oxygen
Number of subjects: 143

Group type: COMPARATOR
Intervention: Sham chamber sessions at 1.2 atmospheres absolute, room air
Number of subjects: 143
Study: 29061154

Group type: EXPERIMENTAL
Intervention: Geriatrician-led admission avoidance hospital at home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient admission
Number of subjects: 0
Study: 25142276

Group type: EXPERIMENTAL
Intervention: Single-point cane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quad cane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hemi-walker
Number of subjects: 30
Study: 25089169

Group type: EXPERIMENTAL
Intervention: Ozone group (standard therapy plus oxygen-ozone treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ozone group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 22178175

Group type: EXPERIMENTAL
Intervention: Fermented ginseng (3g)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-fermented ginseng (3g)
Number of subjects: 24
Study: 19387386

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g per day, 4 doses of 5 g per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (similar in appearance and taste)
Number of subjects: 17
Study: 17459899

Group type: EXPERIMENTAL
Intervention: Stable-state sputa
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Exacerbation sputa
Number of subjects: 104

Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 104
Study: 14707941

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 0
Study: 11803729

Group type: EXPERIMENTAL
Intervention: Amisulpride (100-1200 mg/day)
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Amisulpride (400-800 mg/day)
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 1358

Group type: EXPERIMENTAL
Intervention: Amisulpride (long-term study)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Flupenthixol
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1358
Study: 9617983

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (220 mg every 8 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg every 6 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg every 12 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg every 12 hours) with naproxen sodium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg every 12 hours) with acetaminophen
Number of subjects: 12
Study: 9097765

Group type: EXPERIMENTAL
Intervention: 0.01% SDZ GLC-756 eye drops (n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.1% SDZ GLC-756 eye drops (n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.1% SDZ GLC-756 eye drops (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 24
Study: 2532921

Group type: EXPERIMENTAL
Intervention: Frusemide (30 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Frusemide (30 mg) with ramipril (5 mg) pretreatment
Number of subjects: 6
Study: 788889

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 10 mg/kg/day orally for 7-10 days every 28 days for 1 year
Number of subjects: 113

Group type: COMPARATOR
Intervention: No chemotherapy (Control)
Number of subjects: 113
Study: 31729973

Group type: EXPERIMENTAL
Intervention: Low‐flux bicarbonate hemodialysis with vitamin E‐loaded dialyzers
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low‐flux bicarbonate hemodialysis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hemodialfitration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 18
Study: 28870954

Group type: EXPERIMENTAL
Intervention: Folfox 4
Number of subjects: 48

Group type: COMPARATOR
Intervention: de Gramont
Number of subjects: 48
Study: 25824025

Group type: EXPERIMENTAL
Intervention: Continuous adductor canal blockade
Number of subjects: 90

Group type: COMPARATOR
Intervention: Single shot adductor canal blockade
Number of subjects: 90
Study: 23364815

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 20
Study: 22193786

Group type: EXPERIMENTAL
Intervention: Best practices model within the juvenile court system for early mental health intervention, including screening with the Youth Outcome Questionnaire and treatment involving psychiatric care and in-home behavioral intervention.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening at-risk teenagers with the Youth Outcome Questionnaire.
Number of subjects: 0
Study: 19168876

Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables (Step 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical measures (Step 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein and N-terminal pro B-type natriuretic peptide (Step 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 0
Study: 17237661

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (mean number of sessions 8.7+/‐2.9)
Number of subjects: 2564

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 2564

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (employed patient subgroup analysis)
Number of subjects: 2564
Study: 14742362

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 80
Study: 11682258

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9625586

Group type: EXPERIMENTAL
Intervention: Factor V gene mutation testing
Number of subjects: 27

Group type: COMPARATOR
Intervention: No factor V gene mutation
Number of subjects: 27
Study: 1994682

Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 6093523

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg intramuscularly
Number of subjects: 78

Group type: COMPARATOR
Intervention: Spectinomycin 2.0 g intramuscularly
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 78
Study: 30758491

Group type: EXPERIMENTAL
Intervention: Caring Contacts (11 text messages delivered on day 1, week 1, and at months 1, 2, 3, 4, 6, 8, 10, and 12, plus birthdays)
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Caring Contacts
Number of subjects: 658

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 658
Study: 29901295

Group type: EXPERIMENTAL
Intervention: EFFEX Tribulus
Number of subjects: 173

Group type: COMPARATOR
Intervention: Tribestan
Number of subjects: 173
Study: 27236082

Group type: EXPERIMENTAL
Intervention: Cross-sex hormone treatment (4 weeks and 4 months duration) in MtF and FtM transgender individuals
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (33 male and 44 female)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Baseline assessment of MtF transgender individuals
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Empathy scores assessment
Number of subjects: 57
Study: 23672386

Group type: EXPERIMENTAL
Intervention: 3.5 mL menthol gel
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.5 kg of crushed ice
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3.5 mL of menthol gel and 0.5 kg of crushed ice
Number of subjects: 19

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: menthol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ice
Number of subjects: 19
Study: 20615505

Group type: EXPERIMENTAL
Intervention: Tailor-made telemonitoring program
Number of subjects: 390
Study: 19805781

Group type: EXPERIMENTAL
Intervention: Three-hour seminar followed by three or four clinical sessions
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 86
Study: 16755544

Group type: EXPERIMENTAL
Intervention: Proposed method for estimating the distribution of time to tumour recurrence
Number of subjects: 0
Study: 15476443

Group type: EXPERIMENTAL
Intervention: Ghrelin (0.2 microg/kg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg)
Number of subjects: 2
Study: 11491634

Group type: EXPERIMENTAL
Intervention: Gates‐Glidden drills
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rapid Body Shapers
Number of subjects: 100
Study: 10233876

Group type: EXPERIMENTAL
Intervention: PIXY321 administered subcutaneously in divided doses of 135, 250, 500, 750, and 1,000 micrograms/m2/d during cycles 2 and later
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PIXY321 administered during cycles A-2 and B-1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: PIXY321
Number of subjects: 49
Study: 7982342

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment with bronchodilators and anti-inflammatory agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive and nonconventional therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prognosis of patients requiring mechanical ventilation
Number of subjects: 0
Study: 2508467

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure
Number of subjects: 0
Study: 1000996

Group type: EXPERIMENTAL
Intervention: Unilateral non-dominant temporo-parietal ECT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unilateral dominant temporo-parietal ECT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral non-dominant fronto-frontal ECT
Number of subjects: 0
Study: 31905607

Group type: EXPERIMENTAL
Intervention: 40-g protein drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: isocaloric maltodextrin drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo water control
Number of subjects: 12
Study: 29195547

Group type: EXPERIMENTAL
Intervention: Long RV-LV interval group (≥67 ms)
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: RV-LV time as a continuous variable
Number of subjects: 1342
Study: 25322870

Group type: EXPERIMENTAL
Intervention: Workplace intervention programme tailored according to functional ability and workplace challenges
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual stroke care without workplace intervention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Workplace intervention programme
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADLs) and cognitive assessment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Return to work
Number of subjects: 80
Study: 22911624

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day) plus UDCA (600 mg/day) for 3 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: UDCA (600 mg/day) monotherapy
Number of subjects: 19
Study: 21562081

Group type: EXPERIMENTAL
Intervention: Active video game upgrade package (n = 160)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group (no change, n = 162)
Number of subjects: 322
Study: 18989547

Group type: EXPERIMENTAL
Intervention: Intermittent Mandatory Ventilation (IMV)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Synchronized Intermittent Mandatory Ventilation plus Pressure Support (SIMV+PS)
Number of subjects: 70
Study: 17229660

Group type: EXPERIMENTAL
Intervention: 40% of total daily insulin requirement
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 60% of total daily insulin requirement
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 80% of total daily insulin requirement
Number of subjects: 75
Study: 12620944

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 168

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 168
Study: 10877616

Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normotensive pregnant women
Number of subjects: 16
Study: 9311219

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol and fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhalational anesthesia with nitrous oxide and isoflurane
Number of subjects: 40
Study: 7953033

Group type: EXPERIMENTAL
Intervention: Home-based care (DLPII, n = 33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Out-/in-patient care (DLP-control, n = 33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Phase I controls (n = 70)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Home-based care (DLPII) and Out-/in-patient care (DLP-control)
Number of subjects: 66
Study: 3234467

Group type: EXPERIMENTAL
Intervention: Simvastatin 20‐40 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bezafibrate 600 mg/day
Number of subjects: 16
Study: 31411528

Group type: EXPERIMENTAL
Intervention: 1540-nm nonablative fractional erbium laser
Number of subjects: 15
Study: 28879629

Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 29199898

Group type: EXPERIMENTAL
Intervention: Loss-framed first-person narrative
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Gain-framed first-person narrative
Number of subjects: 461